FDA warned Guangzhou Huli Technology (dba Fantasy Face) for selling an unapproved GLP-1 weight loss drug online.
What happened
FDA reviewed the company's eBay store, fantasyface, in December 2025 and found it offering "Googeer GLP-1 Weight Control Oral Solution" for sale in the United States. FDA said the product's labeling claims, such as weight management, blood sugar balance and body shaping, make it a drug, and that it is a new drug without an approved application. No inspection was reported.
What FDA found
The product is a drug because its labeling claims it treats or affects the body, such as weight management and blood sugar balance.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)The product is a new drug because it is not generally recognized as safe and effective for its labeled uses.
Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)The product is an unapproved new drug because no FDA-approved application is in effect for it.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)Selling and shipping this unapproved drug across state lines is prohibited.
Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks the company to write within 15 working days describing the steps taken to correct the violations and prevent them from recurring, with supporting documents, or to explain why it believes the product is not in violation. The response goes to CDER's Office of Unapproved Drugs and Labeling Compliance by email, with the firm name and identifier 722228 in the subject line.
Who should pay attention
- online sellers and marketplaces listing weight-loss or GLP-1 products
- firms making drug-like claims for supplements or oral solutions
- brands and importers sourcing weight-management products
This is a summary. Read the original letter on fda.gov.